IDEAS home Printed from https://ideas.repec.org/h/spr/mgmchp/978-3-030-02363-8_34.html
   My bibliography  Save this book chapter

Roche Holding’s Acquisition of Genentech

In: Wealth Creation in the World’s Largest Mergers and Acquisitions

Author

Listed:
  • B. Rajesh Kumar

    (Institute of Management Technology)

Abstract

On March 12, 2009, Roche announced a $46.8 billion deal to buy South San Francisco-based Genentech. Genentech over the years were transformed from a startup to an entrepreneurial company which had developed Roche’s best-selling drugs like Avastin, Herceptin, and Rituxan. Roche wanted to absorb the biotech firm’s DNA into its corporate culture. Many of the late-stage clinical trials conducted by Roche involved Genentech products. It was expected that Roche’s main growth could come from expanded uses of Avastin. Unlike Pfizer and Merck, Roche had no interest in generic drugs or consumer products. Roche have become a leader in diagnostics. The acquisition was aimed to improve coordination on product development. With the deal, Roche obtained access to Genentech’s product pipeline beyond the year 2015 and gained access to Genentech’s cash pool of approximately $10 billion. The cumulative return for Roche during the entire acquisition period (initial hostile bid announcement to deal completion) was approximately −9.59%.

Suggested Citation

  • B. Rajesh Kumar, 2019. "Roche Holding’s Acquisition of Genentech," Management for Professionals, in: Wealth Creation in the World’s Largest Mergers and Acquisitions, chapter 34, pages 289-293, Springer.
    • Handle: RePEc:spr:mgmchp:978-3-030-02363-8_34
    DOI: 10.1007/978-3-030-02363-8_34
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:mgmchp:978-3-030-02363-8_34. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.